Hongkou Capital

Hongkou Capital is a private equity firm established in 2020 and located in New York, New York. The firm specializes in investment strategies that include buyouts and growth capital. Hongkou Capital focuses its investments on sectors such as business-to-consumer, electronics, and cleantech. As a Registered Investment Adviser, the firm is committed to managing investments in a way that aligns with regulatory standards and client interests.

Nikhil Nag

Investor

Peter Zhou

Founder and Portfolio Manager

2 past transactions

Day Zero Diagnostics

Venture Round in 2022
The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enabling unprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases. With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings.

Amionx

Series B in 2021
Amionx is a leader in safe battery technology. Our Safe Core technology acts like a circuit breaker to prevent lithium-ion batteries from being the source of a fire or explosion. Our technology is applicable in all battery chemistries including solid state. Safe core protects against overcharge, internal short and external heat.it is focused on safety from the core of the battery outward.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.